Transaction · 0000950170-25-035499

Kerr Douglas

Kerr Douglas, CMO, reported an open-market or private sale at Dyne Therapeutics, Inc. involving 1343.000000 shares for an estimated $15887.69. Reported holdings after the transaction were 94157.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
DYNDyne Therapeutics, Inc.
Filing timeMar 07
Trade dateMar 05, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

DYN price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
DYN since 2025-03-07Filed 551 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000950170-25-035499
Common Stock
Transaction date
Mar 05, 2025
Filed Mar 07, 2025, 09:08 PM · 2d delay
Shares
1.34k sh
$1.18k per share
Estimated value
-$1.58M
Computed from shares × price
Holdings after
94.1k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December…

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes t…

  3. F3

    Includes 92,500 unvested RSUs.

Original filing · 0000950170-25-035499
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

DYN